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Abstract
Epigenetic regulation of tumor suppressor genes (TSGs) has been shown to play a central role in melanomagenesis. By
integrating gene expression and methylation array analysis we identified novel candidate genes frequently methylated in
melanoma. We validated the methylation status of the most promising genes using highly sensitive Sequenom Epityper
assays in a large panel of melanoma cell lines and resected melanomas, and compared the findings with those from
cultured melanocytes. We found transcript levels of UCHL1, COL1A2, THBS1 and TNFRSF10D were inversely correlated with
promoter methylation. For THBS1 and UCHL1 the effect of this methylation on expression was confirmed at the protein
level. Identification of these candidate TSGs and future research designed to understand how their silencing is related to
melanoma development will increase our understanding of the etiology of this cancer and may provide tools for its early
diagnosis.
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Introduction
Aberrant epigenetic modifications are a feature of several human
diseases, including cancer. While several forms of epigenetic
modification are known to exist, so far DNA methylation is the
onlyone showntodirectlytarget DNA and tobefrequently aberrant
in many tumor types [1,2]. By far the most common form of DNA
methylation occurs via covalent modification of cytosine bases which
precede a guanine residue (CpG). The reaction is catalysed by DNA
methyltransferases [3] and results in a methyl group being added to
the 5th position of the pyrimidine ring of cytosine. In mammals the
majority of CpG sequences are methylated, with the exception of
CpG-rich stretches present within the 59 regulatory components of
many genes, termed CpG islands [4]. There is strong evidence
suggesting an inverse relationship between the presence of CpG
island methylation and the level of target gene expression [5],
although this suppression is not always evident. Both hypermethyla-
tion of CpG islands located in the promoters of tumor suppressor
genes (TSGs)andglobalhypomethylation seemto playanimportant
role during cancer development. Often TSGs are not primarily
inactivated through mutation or deletion, but rather through
targeted CpG island methylation.
Melanoma genomics studies have identified a large number of
chromosomal loci that show repeated loss of heterozygosity
(LOH), highlighting widespread chromosomal instability [6,7].
Additionally, aberrant promoter methylation may also occur and
lead to inactivation of TSGs which play a role in progression to
malignancy. During melanomagenesis, well-known TSGs, such as
PTEN, CDKN2A/p16INK4A and RASSF1A often have expression
reduced through CpG island methylation [8,9,10]. In the last
decade, several studies have assessed genome-wide methylation
using the DNA methyltransferase inhibitor 5-aza-2-deoxycytidine
(5AzadC) and identified TSPY, HOXB13 and SYK as novel TSGs
in melanoma [11,12,13].
In a previous study, we combined 5AzadC treatment with
Trichostatin A (TSA), an inhibitor of class I and II histone
deacetylase enzymes, and conducted a microarray-based analysis
on a panel of melanoma cell lines identifying eight highly
‘reactivated’ genes (expression fold change .4), not previously
known to be epigenetically silenced in melanoma [14]. For five of
these genes there was no prior evidence of inactivation by
promoter methylation in any other cancer type. Follow up of these
genes was carried out in a larger panel of melanoma cell lines, in
addition to fresh tumors and melanocyte cultures, using the highly
sensitive Sequenom Epityper assay [15,16] and correlated with
microarray based gene expression levels. Four genes: PPP1R3C
(protein phosphatase 1, regulatory (inhibitor) subunit 3C), ENC1
(ectodermal-neural cortex 1), RARRES1 (retinoic acid receptor
responder also known as tazarotene induced gene 1, TIG1) and
TP53INP1 (tumor protein p53 inducible nuclear protein 1), had
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methylation (.40–60% of CpG sites) in 35–59% of melanoma
cell lines and 6–25% of the fresh tumors.
In order to identify additional epigenetically silenced genes
implicated in melanocytic neoplasia, we have generated new data
from 11 melanoma cell lines using Illumina Infinium Methyla-
tion27 arrays [17]. In order to provide a more complete picture of
methylation in melanoma, these data were integrated with our
previous constitutive mRNA expression [18,19] and post-demeth-
ylation treatment expression data [14] to identify a list of potential
genes for assessment by comprehensive promoter methylation
analysis using the Epityper system in an extended panel of
melanoma cell lines and tumors.
Results
Description of a new pipeline to identify novel candidate
gene CpG islands methylated in melanoma
In our previous study, we used a microarray-based strategy in a
panel of 12 melanoma cell lines treated with 5AzadC and TSA as
an initial screening approach. Select candidate genes were followed
up using the Epityper assay ina much larger panel of melanomacell
lines, as well as a panel of fresh-frozen melanoma samples, normal
melanocyte cultures, and cell lines from other cancer types. We
identified four genes, PPP1R3C, ENC1, RARRES1 and TP53INP1
that were not previously known to be silenced by DNA methylation
in melanoma [14].
In order to use more robust criteria to select the genes
epigenetically silenced during the development of melanocytic
tumors, we have generated new data on 11 melanoma cell lines
using Illumina Infinium Methylation arrays. The Infinium
Methylation chips interrogate 27,578 CpG loci covering more
than 14,000 genes. We screened 11 melanoma cell lines from our
pilot study [14], which we compared to pools of melanocytes from
several donors.
These new data were then integrated with previous data-sets of
global mRNAexpression [18,19] and expression post-demethylation
treatment [14] in order to focus on identifying additional candidate
TSGs down-regulated through promoter methylation. Genes were
further filtered to identify those in which $60% methylation
correlated with a 4-fold decrease in mRNA levels in at least 2
samples, together with an average post-demethylation re-expression
fold-changeof.4 across thepanelof11melanoma lines (Figure 1).
This gave a set of 26 genes, from which we then removed oncogenes
(ADM, ENPP2, RAC2, SERPINE1), genes we had previously
identified (PPP1R3C), those without a described function e.g.
annotated as ‘‘orf’’ (C10orf116, SLC25A38, CCDC109B), and false
positives on the Infinium Methylation chips (i.e. multiple instances
where cell lines were methylated on the HumanMethylation27
BeadChip but showed no re-expression with 5AzadC+TSA
treatment; EEF1A2, HSPA2).
Figure 1. Flow through of the cross-platform array integration.
doi:10.1371/journal.pone.0026121.g001
Epigenetic Gene Silencing in Human Melanoma
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26121These additional filters resulted in 12 genes remaining for initial
follow up (COL1A2, CRABP2, CRIP1, FAM46B, GATA2, IGFBP4,
LOX, RGC32, THBS1, TNFRSF10D, UCHL1 and VAMP8). The
genes were further filtered by validating the differences in their
expression levels pre- and post-treatment. Transcript levels of
these 12 genes were assessed by qRT-PCR in the 5 cell lines with
the highest expression differences before and after treatment.
Selecting only the genes with a .4–fold average qRT-PCR
expression change and the presence of CpG islands in the
promoter gave a final list of 10 genes: COL1A2, CRABP2, CRIP1,
GATA2, IGFBP4, LOX, RGC32, THBS1, TNFRSF10D and
UCHL1. While the absolute value of the fold-changes varied
somewhat between the two methodologies, there was generally
good agreement between the microarray and qRT-PCR results
(Figure S1). Importantly, for each of these 10 genes both
techniques showed a .4–fold average change in expression after
drug treatment.
We then quantitated the degree of methylation of these 10
candidate genes using mass spectrometry of base-specific cleaved
amplification products (Sequenom Epityper assay [15,20]). This
technique was applied to a panel of 45 melanoma cell lines, 30
fresh melanoma tumor samples, and 2 independent pools of
cultured melanocytes for comparison as the non-malignant control
cell type. Each gene promoter was divided into one or more
amplicons, within a region comprising 2500 bp upstream of the
transcription start site and covering the CpG islands described in
the UCSC genome browser. These amplicons were then amplified
by PCR (Table S1) and subjected to the Epityper assay. Three
genes were not considered further as they either failed to give any
analysable data, probably due to the high CpG density of the
region (CRABP2), or showed no differences in methylation profiles
between melanocytes and the melanoma cell lines (LOX and
RGC32).
For each gene, the amplicons included in the analysis were those
with different average methylation values of .20% in the entire
panel of melanoma cell lines and with ,10% methylation in
melanocytes (Figure S2). These informative CpG sites were then
scored in each amplicon defining the CpG island for each gene.
Only the CpG sites presenting high methylation ratios (as defined
below)inmelanoma cell lines were averaged forthefinal percentage
of methylation (% of methylation). This allowed grouping of the
melanoma cell lines following their % of methylation: no/low
methylation (0–20%), medium (20–50%) and high methylation
(.50%). We then defined the average % of methylation for each
gene as the average value across the melanoma cell line panel which
was then compared to melanocytes.
Integrating the degree of methylation and the level of mRNA
expression, as assessed by previous Affymetrix microarray analysis
[19] gave high correlation coefficients (Spearman coefficients=
20.75/20.82/20.6/20.52 respectively, p,0.005) for four genes:
COL1A2, THBS1, TNFRSF10D and UCHL1.
Expression of the COL1A2, THBS1, TNFRSF10D and
UCHL1 genes is inhibited by CpG island methylation in
melanoma cell lines
Following 5AzadC+TSA treatment, COL1A2 and THBS1
transcript levels were increased by an average of 58-fold in 9 of
12 cell lines and 40-fold in 8 of 12 cell lines respectively (Table
S3). For TNFRSF10D, 5 cell lines showed a 5-fold average increase
in expression.
In melanoma cell lines, the average % of methylation for these
genes was 24%, 31% and 66% respectively. The methylation
levels of these genes in the melanocyte pools were close to
background (between 2 to 9%).
The 59UTR regions around the transcription start sites of
COL1A2 and THBS1 were both divided into 5 amplicons, while 4
amplicons were designed to cover the 59UTR and first exon of
TNFRSF10D (Figure S2). For each of the three genes, the
amplicons closest to the transcription start (within 1000 bp)
showed high levels of methylation in the melanoma samples,
which inversely correlated with mRNA expression (Table S1).
Table S4 summarizes the number of CpG sites scored for the
definition of the % of methylation for each gene (19, 15, 37 and 19
for COL1A2, THBS1, TNFRSF10D and UCHL1 respectively).
Over fifty percent (21/40) of the melanoma cell lines had no
COL1A2 mRNA expression, which correlated with a high degree
of COL1A2 promoter methylation in 67% of this subset. The other
19 cell lines with detectable COL1A2 mRNA expression all showed
,20% of methylation, with the exception of 3 lines (MM415,
MM229 and D05). (Figure 2a - Figure S3a).
For TNFRSF10D, 31 of 43 (72%) melanoma cell lines had no
mRNA expression. Of the 31 lines not expressing TNFRSF10D,2 8
(90%) showed .60% of methylation (Figure 2b - Figure S3b).
For THBS1, 15 of 43 (35%) melanoma cell lines had no mRNA
expression. Eight of the 15 (53%) lines with no THBS1 mRNA
showed a high .50% methylation (Figure 2c - Figure S3c).
Following 5AzadC+TSA treatment, UCHL1 expression was
increased by an average of 18-fold in 10 out of 12 cell lines. For the
Epityper assay, the region around the 59UTR and transcription
start site of UCHL1 was divided in to 4 amplicons, also covering
both exons 1 and 2 (Figure S2). While amplicons 2 and 6 did not
show any differential methylation between melanoma cell lines
and melanocytes (Table S1), amplicons 4 and 8 showed specific
profiles of methylation in melanoma cell lines inversely correlated
with mRNA expression (Spearman=20.53). A majority (56%) of
the melanoma cell lines had no UCHL1 mRNA expression, which
correlated with a high degree of UCHL1 promoter methylation in
79% of them (5% of methylation in melanocytes compared to an
average of 42% in melanoma cell lines, range=29–95%). The
melanoma cell lines with high UCHL1 mRNA expression have
,20% methylation (Figure 2d - Figure S3d).
Next, we assessed protein levels for THBS1 and UCHL1 (since
robust target-specific commercial antibodies are available) by
western blot analysis (Figure 3). There was a high correlation
between mRNA and protein expression (Pearson=0.84 and 0.51
for UCHL1 and THBS1 respectively), and an inverse correlation
between protein expression and the methylation profile (Spear-
man=20.52 and 20.33 for UCHL1 and THBS1 respectively).
Confirmation of candidate gene promoter methylation in
fresh-frozen melanoma tumors
Simultaneously, in the Epityper assay, we included 30 fresh-
frozen melanoma tumor samples and found that 13%, 15% and
30% of them respectively were methylated for COL1A2, THBS1
and TNFRSF10D (Table 1). On average, the COL1A2 and
TNFRSF10D promoters appeared .10–fold more methylated in
melanoma cell lines compared to melanocytes, and 6-fold higher
in the fresh tumors (Figure S4). THBS1 promoter methylation
levels were 3.5 and 2 times higher in melanoma cell lines and
tumors respectively.
The UCHL1 promoter appeared to be 8-fold more methylated
in melanoma cell lines compared to melanocytes, and 4-fold more
methylated in the 30 fresh tumors compared to the same control.
Since mRNA levels were not assessed in the tumors, we are unable
to correlate the proportion of methylation with expression in these
samples. The observed methylation rates in tumors are lower than
in the melanoma cell lines, as expected due to stromal
Epigenetic Gene Silencing in Human Melanoma
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26121contamination, which will likely have the effect of decreasing the
observed overall percentage of methylation of the DNA assessed.
Methylation of candidate gene promoters in other cancer
types
In order to assess the possible specificity of methylation of the
four candidate genes to melanoma, we repeated the same Epityper
assays on a limited number of cell lines from cancers of the colon,
esophagus and brain (glioma). These different cancer types were
assessed to determine whether the candidate genes might play a
more general role in tumor suppression. Two cell lines from each
tumor type were assessed for their methylation status for COL1A2,
THBS1, TNFRSF10D and UCHL1. Using the same cut off as for
the melanoma cell lines and tumors, the percentage methylation
for the COL1A2 and UCHL1 CpGs islands was 65% and 82% in
the esophageal cancer cell lines respectively and 92% and 90% in
the colon cancer cell lines respectively. While THBS1 was only
methylated in the colon cancer cell lines (43% methylation),
TNFRSF10D appeared to be the only gene methylated in the
glioma lines (33%) (Table 1).
Discussion
The objective of this study was to combine different array
platforms to strengthen the identification of novel TSGs
inactivated by promoter methylation in melanoma. Selection of
candidate genes was based on reduced expression in a panel of
melanoma cell lines which correlated with a high methylation
profile, and lack of the same observation in melanocyte cultures.
Using these criteria we identified and subsequently confirmed four
genes silenced by DNA methylation in melanoma. We found 24%,
31%, 66% and 42% of cell lines and 13%, 15%, 30% and 21% of
tumors were methylated for COL1A2, THBS1, TNFRSF10D and
UCHL1 respectively.
Each of these four genes had previously been linked to
melanoma. Muthusamy et al. and Koga et al. [12,21] identified
COL1A2 as methylated in 35% (7/20) to 89% (16/20) of melanoma
Figure 2. Distribution of the melanoma cell lines according to their methylation status for a. COL1A2, b. TNFRSF10D, c. THBS1, d.
UCHL1. The melanoma cell lines were grouped following their mRNA expression level, no or high expression. Methylation levels were determined by
Epityper assay.
doi:10.1371/journal.pone.0026121.g002
Figure 3. Western blot analysis of THBS1 and UCHL1 protein expression.
doi:10.1371/journal.pone.0026121.g003
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of several human cancer cell lines, Paz et al. reported reactivation of
THBS1 expression following 5AzadC treatment in all 18 melanoma
cell lines analysed [22]. Liu et al. [23] showed TNFRSF10D promoter
methylation in 85% of their melanoma cell lines (17/20) and 80% of
their fresh melanoma tumor samples (32/40). In their study of the
moleculareffectsoflowdoseof5AzadC(Decitabine)on8melanoma
cell lines, Halaban et al. [24] presented evidence for changes in
expression of COL1A2, TNFRSF10D, THBS1 and UCHL1.H e r e ,w e
further document the link between these genes and melanoma by
confirming the correlation between methylation and expression of
these genes in a larger panel of melanoma cell lines. In our study, we
assessed 45 melanoma cell lines, 30 fresh tumor samples and
correlated methylation status and mRNA expression levels to
observations made in pooled melanocytes. Furthermore, while the
majority of the previous methylation studies were based on the
analysis of gene re-expression post-5AzadC treatment but not on
assesment of promoter methylation per se, we present here a study
design which goes beyond 5AzadC treatment to include a precise
CpG methylation profile via the Epityper assay, a sensitive and high-
throughput method for DNA methylation analysis.
Within the large collagen family, collagen type I is the most
abundant, structural component of healthy connective tissue and
consists of aheterotrimer oftwo a1(C OL1A 1)ando nea2(C OL1A 2)
chains. Cellular p53 negatively regulates COL1A2 through TGF-b
signalling in normal dermal fibroblasts [25]. Evidence for COL1A2
aberrant promoter methylation has been described in different cancer
cells such as breast cancer, medulloblastoma, hepatoma, colorectal
cancer [26,27,28] and more recently in melanoma [12,21]. Sengupta
et al. describe the possible advantages a decrease in collagen synthesis
may confer on cancer cells, including faster cell growth and increased
tumorigenic potential [28].
THBS1 (also known as TSP-1) encodes the glycoprotein
thrombospondin, which is generally considered a tumor suppres-
sor and mediates cell-to-cell and cell-to-matrix interactions
important for platelet aggregation and angiogenesis [29].
Down-regulation of THBS1 by methylation has been described
in several cancer types such as neuroblastoma [30,31], colorectal
[32,33,34] and stomach cancers [35,36,37]. Promoter hyper-
methylation of THBS1 was detected in brain metastases of solid
tumors such as, melanoma, lung, ovarian and breast carcinomas
[38] and more recently associated with bad prognosis in penile
squamous cell carcinoma [39].
The protein encoded by TNFRSF10D (TRAIL4, DcR2) is a
member of the TNF-receptor superfamily containing an extracel-
lular TRAIL-binding domain and a truncated cytoplasmic death
domain. This receptor does not induce apoptosis but has been
shown to play an inhibitory role in TRAIL-induced apoptosis [40].
Like all the other genes encoding TRAIL receptors, TNFRSF10D
expression is directly regulated by p53 and regulates cellular
chemosensitivity [41]. TNFRSF10D promoter hypermethylation
has been described as a mechanism of inactivating this gene in
several cancer types [42,43,44].
The current study details UCHL1 (ubiquitin COOH-terminal
esterase L1) inactivation by promoter methylation in melanoma.
This gene encodes a peptidase activator of the ubiquitin-dependent
proteindegradation pathway. Originally identified inneuronsand in
cells of the diffuse neuroendocrine system, mutations in this gene
have been associated with Parkinson disease [45,46]. UCHL1 has
been attributed important roles in multiple cellular processes such as
proliferation, cell cycle, apoptosis and intra-cellular signalling. Its
role in tumorigenesis, TSG or oncogene, seems to be dependent on
the tumor type [47,48]. UCHL1 methylation has been reported in
multiple tumors [49], such as esophageal [50], gastric [36,51], renal
[52], prostate [53], head and neck squamous [47], ovarian [54],
hepatocellular and colorectal cancers [49,55]. Some studies even
suggested the use of UCHL1 methylation as a biomarker for
diagnosisandprognosisofcertaintumors[50,55,56].Lietal.recently
showed in nasopharyngeal carcinoma cell lines that UCHL1 was a
member of the p53/p14ARF/MDM2 complex [48]. Through its
deubiquitinating activity, UCHL1 is involved in the stabilisation of
p53andp14ARF.Inparallel,italsodecreasestheamountofMDM2
by promoting its degradation through ubiquitination. A reduction in
UCHL1 expression has previously been associated with poor
survival in melanoma [57]. Our study confirms that this is likely to
occur via hypermethylation of the UCHL1 regulatory region.
Interestingly, all four genes (COL1A2, THBS1, TNFRSF10D and
UCHL1) we identify here as methylated in melanoma, encode
components that fit within the p53 ontology pathway. Moreover,
two of the genes we had identified in a previous methylation study
are also associated with p53 function, either being induced by p53
(ENC1) or interacting with p53 (TP53INP1) [14]. In melanoma,
direct inhibition of p53 by mutation is relatively infrequent (see
[58] for review). Our finding of six candidate TSGs linked to p53
function that are subject to methylation in melanoma might
indicate alternative mechanisms by which these cells abrogate p53
downstream signalling in this tumor type. Further functional
validation of these methylated genes is necessary to confirm their
importance in melanocytic neoplasia, their candidacy as potential
TSGs, as well as their possible relationship to p53 status.
Table 1. Summary of COL1A2, THBS1, TNFRSF10D and UCHL1 methylation in melanocytes, melanoma cell lines, fresh-frozen
melanoma tumors and other cancer cell lines.
% of methylation
in melanoma
other cancer cell
lines
In melanocytes
In MM cell
lines MM/mel
In Fresh
tumors FT/Mel
esophageal
cancer glioma
colon
cancer
Col1A2 2% 24% 10.48 13% 5.76 65% 5% 92%
THBS1 9% 31% 3.43 15% 1.79 2% 4% 43%
TNFRSF10D 5% 66% 13.03 30% 6.05 2% 33% 2%
UCHL1 5% 42% 8.10 21% 4.05 82% 5% 90%
Ratios to melanocytes are presented for the % of methylation in melanoma cell lines and melanocytes (MM/mel) and the fresh-frozen tumors (FT/mel).
MM malignant melanoma.
mel melanocytes.
FT fresh-frozen tumors.
doi:10.1371/journal.pone.0026121.t001
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to identify a short list of robust methylated genes in melanoma. We
confirm previous reports that COL1A2, THBS1, TNFRSF10D and
UCHL1 are highly methylated in melanoma, thus providing further
evidence that these genes are highly important in melanocytic
neoplasia.
Others have used somewhat similar integrative approaches
[59,60]. Sjaputera et al. [60] compared methylation array data
with expression data with an arbitrary methylation cut off; and
Loss et al. [59] integrated methylation and expression data
followed by logistic regression to identify the most significantly
affected genes. However, they did not include re-expression data
following 5azadC treatment, or quantification of the degree of
methylation using the Epityper or a similar assay.
While these other two studies were done on different cancer
types (breast cancer and lymphomas), one common methylated
gene, COL1A2 was identified. Taken together, this suggests that
COL1A2 is a gene for which methylation is more generally
associated with tumorigenesis across different cancer types.
Materials and Methods
Cell Culture
A panel of 12 melanoma cell lines derived from primary
cutaneous melanomas or their metastases were used [14]. All cell
lines were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum as described previously [19,61]. Primary human
melanocytes were obtained from neonatal foreskins and cultured
in 10% heat-inactivated fetal calf serum (CSL, Melbourne,
Australia) in RPMI-1640 medium supplemented with 100 U/ml
penicillin, 100 mg/ml streptomycin, 3 mM HEPES with the
addition of 6 ng/ml cholera toxin and 16.2 nM phorbol 12-
myristate 13-acetate (PMA) (Sigma Chemical Co., St. Louis, MO)
as previously described [62]. All tissue was taken with written
informed consent under a protocol approved by the Queensland
Institute of Medical Research Human Research Ethics Committee
(HREC), approval number H0311-084 (P726).
The 2 colorectal cancer cell lines Co115 and LIM 2405,
esophageal cancer cell lines OE19 and OE33, glioma cell lines
T46 and T50 were purchased from the American Type Culture
Collection (http://www.atcc.org/).
DNA extraction, Bisulfite Conversion and Illumina
Infinium Methylation27 Array Hybridization
QIAGEN DNeasy Blood and Tissue Kits were used to isolate
genomic DNA from cells in log phase growth as per the
manufacturer’s instructions (QIAGEN,Hilden). All samples were
run on an Agilent Bioanalyzer (Agilent, CA, USA) using a DNA
12000 LabChip kit to check for DNA integrity, purity and
concentration. 500 ng of genomic DNA from 11 melanoma cell
lines and a reference pool of melanocytes derived from several
donors were bisulfite treated using an EZ-96 DNA methylation kit
(Zymo Research, CA, USA) as per the manufacturer’s instructions.
They were then hybridized to Infinium Methylation BeadChips
(Illumina,CA,USA) containing 27,578 CpG loci covering more
than 14,000 genes [17]. All reagents and procedures for washing,
detection and scanning were performed according to the
BeadStation 5006system protocols (Illumina, CA, USA).
Beadarray methylation analysis
Percent methylation (beta) was calculated from the ratio of
fluorescent signal intensities of the methylated (M) and unmethy-
lated (U) alleles, for each sample at each specific CpG site, using
the equation beta=Max(M,0)/[Max(M,0)+Max(U,0)+0]6100.
On this scale unmethylated sites are represented by beta values
close to zero, while heavily methylated sites show values
approaching 100%. We then expressed each site specific
melanoma cell line methylation value as a delta difference,
compared to that of melanocytes. In this way negative values
represented a cell line and site specific decrease in methylation,
while positive scores indicated a relative increase in the degree of
methylation. The provided manifest file linked individual meth-
ylation sites to official gene symbols, which we used to associate the
methylation data to that of mRNA expression and demethylation,
as described below. The data are MIAME compliant and have
been deposited in Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo/) under accession number GSE28356.
Microarray gene expression profiling
These data (GSE7127) were generated as part of previously
published studies [18,19]. Briefly, 5 mg of total RNA from 35
melanoma cell lines and one melanocyte foreskin pool were
applied to Eukaryotic One-cycle Target Labelling and Control
Reagents kits, according to the manufacturer’s instructions
(Affymetrix, CA, USA), and 15 mg of the resulting fragmented
cRNA mixtures was then hybridized to an Affymetrix Human
Genome U133 Plus 2.0 Array for 16 hr at 45uC. Chips were then
washed and streptavidin phycoerythrin post-stained, before
scanning on an Affymetrix GeneChip Scanner 3000. Relative
expression values for each probe set were generated from the raw
image data files using the Affymetrix PLIER algorithm in
ArrayAssist 1 Version 4.20 (Stratagene). The resulting data were
imported into GeneSpring GX v7.3 (Agilent Technologies) where
data values less than 0.1 were set to 0.1 prior to log transformed to
base 2. The expression values were then centrally normalized to
the median expression value for each sample and the median
expression value for each probe set. For the current study,
expression data for each of the 11 melanoma cell lines for which
we have Illumina Infinium Methylation Array were expressed as a
ratio, per gene symbol, compared to that of the included
melanocyte cell line. In this way we are able to match a single
methylation value to an expression estimate for each of the 11 cell
lines with matched data.
5AzadC demethylation profiling
These data were generated as part of a previously published
study [14] (GSE32492). Briefly, cells were split to 20% confluence
24 hr prior to commencing a 3-day treatment with either 5 mMo f
5AzadC (Sigma) from 100 mM 50% acetic acid dissolved stock, or
mock treated with the same volume of phosphate buffered saline
(PBS)/50% acetic acid. The 3-day incubation was followed by a 4-
hr incubation with 300 nM TSA (Sigma) prior to total RNA
extraction from cells in log phase growth (RNeasy Midi-kits –
Qiagen, Hilden) and on-column DNase digestion. Samples with
an Agilent Bioanalyzer (Agilent, CA, USA) determined RNA
integrity number (RIN) of .8.0 were used for microarray analysis.
Biotinylated cRNA were prepared from 500 ng of total RNA
using an Illumina TotalPrep RNA Amplification Kit (Ambion,
TX, USA) and 1500 ng was hybridized to Sentrix Human-6
Expression version 2 BeadChips (Illumina, CA, USA) prior to
washing, detection, and scanning according to the BeadStation
500GX system protocols (Illumina).
Expression profiles generated for each cell line before and after
drug treatment (expressed as a fold-change ratio) showed that
across the panel of 12 cell lines a total of 8,144 non-redundant
genes were re-expressed with .2-fold change after treatment
(between 1,457 and 3,386 genes in individual samples). Genes
reactivated in all 12 cell lines were removed from further analysis
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treatment, or promoter demethylation of genes normally silenced
within the melanocytic lineage.This filtering left 3125 genes to be
considered from cross-analysis with the Beadarray27 methylation
and U133 Plus 2.0 mRNA expression data described above.
Combining mRNA profiling, demethylation and
Beadarray27 data across 11 melanoma cell lines
Fold-change expression profiling data (compared to melanocyte
pool), fold-change demethylation data (compared to matching
untreated cell line) and Illumina methylation profiling data (delta
% methylation compared to the melanocyte pool) for each of the
11 cell lines for which all data were available, were imported into
Microsoft Excel and linked via official gene symbol (HUGO Gene
Nomenclature Committee). Data filters were then applied to each
of the three data types in order to identify genes with clear
evidence of methylation (through both the presence of increased
methylation values, and with increased expression following
demethylation) and evidence of reduced expression compared to
the melanocyte pool. Genes symbols were filtered to identify those
in which at least 2 samples showed $60% methylation
(Beadarray27) correlated to an average post-demethylation re-
expression fold-change of .4 and 4-fold mRNA global decrease
across the panel of 11 melanoma lines. From this set of 26 genes,
after removing oncogenes (ADM, ENPP2, RAC2, SERPINE1),
genes we had previously identified (PPP1R3C), those without a
described function e.g. annotated as ‘‘orf’’ (C10orf116, FLJ20551,
FLJ20647), and the presence of false positives on the Infinium
Methylation chips (i.e. multiple instances where cell lines were
methylated on the Beadarray27 but showed no re-expression with
5AzadC treatment; EEF1A2, HSPA2), 16 genes remained for
initial follow up (COL1A2, CRABP2, CRIP1, FAM46B, GATA2,
IGFBP4, LOX, RGC32, THBS1, TNFRSF10D, UCHL1,
ALDOC, COL12A1, GALM, VAMP5 and VAMP8). Of these,
12 genes (COL1A2, CRABP2, CRIP1, FAM46B, GATA2,
IGFBP4, LOX, RGC32, THBS1, TNFRSF10D, UCHL1 and
VAMP8) were subject to further validation as described below.
Quantitative RT–PCR
mRNA extraction & expression array data were obtained as
previously described [14,18,19]. To confirm the validity of the
microarray expression data, the mRNA levels were assessed by
quantitative reverse transcriptase–polymerase chain reaction
(qRT–PCR) (see Table S2 for primer sequences) in the 5 cell
lines with the highest expression differences before and after
5AzadC treatment. First-strand cDNA synthesis was performed
with 3 mg total RNA for each sample in a total volume of 20 ml
using Superscript III reverse transcriptase and random primers
(Invitrogen, CA, USA). Subsequent PCR reactions were carried
out on a Corbett RotorGene 6000 (Corbett Research, Australia)
using SYBR Green RT–PCR Master Mix (Applied Biosystems,
Foster City, CA). CLTA (clathrin light chain mRNA) was chosen
as the normalization control transcript based on minimum
variation across the cell lines as assessed by microarray [14].
EPITYPER Assay
The Sequenom EpiTYPER assay is based on in-vitro
transcription and base-specific cleavage of a PCR amplicon and
the subsequent analysis of the resulting RNA fragments by
MALDI-TOF mass spectrometry [15,20].
EZ-96 DNA methylation kits (Zymo Research, CA, USA) were
used for bisulfite treatment of 1 mg of genomic DNA from 44
melanoma cell lines, 1 nevus cell line, 2 colorectal cancer cell
lines (Co115 and LIM 2405), 2 esophageal cancer cell lines
(OE19 and OE33), 2 glioma cell lines (T46 and T50), and 30
fresh-frozen melanoma tumors. DNA from pools of melanocytes
was used as reference. Each gene promoter was divided into
several amplicons (Table S1). The target regions were then
amplified using the primer pairs containing a T7-promoter tag
(forward: 59-AGGAAGAGAG-fw primer-39,r e v e r s e :5 9-CAG-
TAATACGACTCACTATAGGGAGAAGGCT-rev primer-39)
to allow further in vitro transcription. One microliter of modified
DNA was used for the PCR reactions carried out in a total
volume of 5 ml. Unincorporated dNTPs were dephosphorylated
by incubation at 37uC for 40 min in the presence of shrimp
alkaline phosphatase (SAP) (Sequenom). Two microliters of this
SAP-treated PCR mixture were used as a template in a 7 ml
transcription reaction containing RNase A and T7 polymerase
(Sequenom). Transcription and digestion were performed simul-
taneously at 37uC for 3 h. After the addition of 20 mlo fH 2O and
6 mg of CLEAN resin (Sequenom), 22 nl of the cleavage
reactions were dispensed onto silicon chips preloaded with
matrix (SpectroCHIPS, Sequenom). Mass spectra were collected
using a MassARRAY mass spectrometer (Bruker-Sequenom) and
analysed using proprietary peak picking and signal-to-noise
calculations (Sequenom Epityper v1.0.5).
The relative amount of methylation (% methylation) was
determined by comparing the signal intensities between the mass
signals of methylated and non-methylated template.
For data analysis only unique CpG units (units can contain one
or more consecutive CpG dinucleotides) are included. CpG units
overlapping with other cleavage fragments in the mass spectrum
were excluded from data analysis. CpG methylation ratios were
filtered using an uncertainty threshold of 10%. Only data values
(CpG methylation ratios) with an estimated error smaller than
10% were included in the analysis. This filtering ensured that only
precise data values were used for downstream calculation.
For each gene, the amplicons presenting no significant difference
in methylation between melanoma cell lines and melanocytes were
dropped from the analysis (Figure S2). In each amplicon, the
informative CpG sites were then scored defining the CpG island for
each gene. Only the CpG sites presenting high methylation levels in
melanoma cell lines were included in the final percentage of
methylation. The average % of methylation for each gene was then
defined as the average value across the melanoma cell line panel
which was compared to melanocytes.
Statistical Analysis
Spearman test was applied for the correlation between mRNA
expression and methylation of the genomic region assessed. A t-
test (t=r/Sr) was performed to obtain the significance
(Sr=(12r
2)/n) of the Spearman coefficient.
Western blot analysis
Total cell lysates from 1.10
7 cells were generated as previously
described [63]. Samples (30 mg protein) were resolved by 10%
SDS-polyacrylamide gel electrophoresis, and transferred to
nitrocellulose membranes. Antibodies raised against the following
proteins were used for Western blotting: anti-THBS1 (ab88529, 1
in 1,000 dilution; Abcam, Cambridge, UK), anti-UCHL1, (1 in
1,000 dilution; Sigma Prestige antibodies, St. Louis, MO), and
anti-GAPD (1 in 5,000 dilution; R&D Systems, Minneapolis,
MN). Detection was performed using the appropriate peroxidase-
conjugated secondary antibody and a Western Lightning
chemiluminescent reagent plus kit (PerkinElmer LAS, Inc.,
Boston, MA).
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Figure S1 Comparative expression between microarray
and qRT-PCR for 12 candidate genes. Plotted are the mean
fold-change values for 5 cell lines with the highest expression
differences before and after 5Aza-dC treatment.
(PDF)
Figure S2 UCSC browser for localisation of the ampli-
cons used for the Epityper assays. The alignments show the
localisation of the Illumina probes.
(PDF)
Figure S3 Distribution of the melanoma cell lines
according to their methylation status for a. COL1A2
mRNA expression, b. TNFRSF10D mRNA expression, c.
THBS1 mRNA and protein expression, d. UCHL1 mRNA
and protein expression. The melanoma cell lines were
grouped following their methylation profiles: high (.50%),
medium (20–50%) and no/low (0–20%).
(PDF)
Figure S4 Epityper results for the COL1A2, THBS1,
TNFRSF10D and UCHL1 promoters in melanocytes, 45
melanoma cell lines, 30 fresh melanoma tumors and cell
lines from other tumor types (colon, esophageal and
glioma). The software uses a color coding to show the range of
methylation: red to yellow for 0 to 100% of methylation. While the
melanocytes show no methylation across the amplicon, the
melanoma cell lines and fresh tumors present different patterns
of methylation.
(PDF)
Table S1 Primers for PCR. Each gene promoter was divided
into different amplicons. The target regions were then amplified
using the primer pairs and annealing temperatures defined by the
MethPrimer program.
(XLS)
Table S2 Primers for qRT-PCR.
(XLS)
Table S3 Levels of gene reactivation in a panel of 12
melanoma cell lines post-5AzadC+TSA treatment.
(PDF)
Table S4 Informative CpG sites count. For each gene, only
the amplicons presenting a significant methylation profile
difference between melanoma cell lines and melanocytes were
scored. In each amplicon, only the informative SpG sites were
counted for the final % of methylation value for each gene.
(PDF)
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